Shares may have been likely to fall no matter what the company reported.By no means were Amgen's (AMGN -5.54%) second-quarter numbers "bad." Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising expenses. The pharmaceutical company's outlook remains optimistic as well.Yet, S&P Global Market Intelligence data indicates Amgen shares are down 5.9% as of 12:46 p.m. ET today. The prompt for the sell-off is mostly an earnings miss, but the actual ...

Amgen (AMGN) reported second-quarter 2024 adjusted earnings of $4.97 per share, which beat the Zacks Consensus Estimate of $4.93. Earnings declined 1% year over year due to higher operating costs and higher interest expenses.Total revenues of $8.39 billion beat the Zacks Consensus Estimate of $8.31 billion. Total revenues rose 20% year over year.Total product revenues increased 20% from the year-ago quarter to $8.04 billion. Higher volumes were partially offset by lower selling prices of several drugs. Volu ...

Amgen TodayAMGNAmgen$313.39 -15.56 (-4.73%) 52-Week Range$248.38▼$346.85Dividend Yield2.87%P/E Ratio44.77Price Target$312.63Add to WatchlistAmgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market. The Health Care Select Sector SPDR Fund NYSEARCA: XLV has returned 9%.Let's start by exploring Amgen's main products and growth opportuni ...

Amgen Inc. (NASDAQ:AMGN) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Bob Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Jay Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Salveen Richter - G ...

Amgen (AMGN) reported $8.39 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 20.1%. EPS of $4.97 for the same period compares to $5.00 a year ago.The reported revenue represents a surprise of +0.98% over the Zacks Consensus Estimate of $8.31 billion. With the consensus EPS estimate being $4.93, the EPS surprise was +0.81%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I.R.S. Emp ...

Amgen (AMGN) came out with quarterly earnings of $4.97 per share, beating the Zacks Consensus Estimate of $4.93 per share. This compares to earnings of $5 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.81%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $3.76 per share when it actually produced earnings of $3.96, delivering a surprise of 5.32%.Over the last four quarters, t ...

Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com THOUSAND OAKS, Calif. (Aug. 6, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: • Fo ...

Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6.Analysts expect the Thousand Oaks, California-based company to report quarterly earnings at $5.01 per share, up slightly from $5.00 per share in the year-ago quarter. Amgen is projected to report quarterly revenue of $8.33 billion, compared to $6.99 billion a year earlier, according to data from Benzinga Pro.On Aug. 2, Amgen declared a $2.25 per share dividend for the third quarter of 20 ...

THOUSAND OAKS, Calif., Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will be paid on September 6, 2024, to all stockholders of record as of the close of business on August 16, 2024.About Amgen   Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, A ...